|
 Patients given the company's drug, eptinezumab, experienced a
statistically significant reduction in monthly migraine days in both
300 mg and 100 mg dosages.
In the study, patients receiving the 300 mg dosage experienced a
reduction of 4.3 days from baseline in monthly migraine days, while
those on the 100 mg saw a reduction of 3.9 days. Patients on the
placebo experienced an average of 3.2-day reduction.
Migraine affects about 36 million Americans and is considered the
6th most disabling disease in the world characterized by recurrent
episodes of moderate-to-severe headaches accompanied by nausea,
vomiting, and sensitivities to light and sound.
Alder joins a crowded field of companies racing to develop a new,
more effective migraine treatment.
[to top of second column] |
Apart from Alder, Amgen Inc, Eli Lilly Co and Teva Pharmaceutical
Industries Ltd are all developing drugs to target calcitonin
gene-related peptide, or CGRP, a protein involved in pain-signaling
during migraine.
Alder said it expects to complete enrollment later this year in
another late-stage trial testing patients with chronic migraine.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
